{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', '7.5.4.', 'Electrocardiogram', 'Triplicate standard 12-lead ECGs, with readings approximately 1 minute apart, will be recorded', 'as specified in the Schedule of Assessments (Table 1). Patients should be supine for at least 5', 'minutes before each ECG is obtained. The electrophysiological parameters assessed will be', 'rhythm, ventricular rate, RR interval, PR interval, QRS duration, QT interval, Bazett-corrected', 'QT interval (QTcB), and Fridericia corrected QT interval (QTcF).', 'When ECG and blood sample collection occur at the same time, ECGs should be performed', 'before blood samples are drawn.', 'The Investigator or qualified designee will review all ECGs to assess whether the results have', 'changed since the Baseline visit and to determine the clinical significance of the results. These', 'assessments will be recorded on the eCRF. Additional ECGs may be collected at the discretion', 'of the Investigator. Recordings will be archived according to the Study Manual.', '7.5.5.', 'Clinical Laboratory Assessments', 'The following clinical laboratory tests will be evaluated by a central laboratory. Specific', 'instructions for transaminase elevations are provided in Section 6.2.3.1. For any other', 'unexplained clinically relevant abnormal laboratory test occurring after IMP administration, the', 'test should be repeated and followed up at the discretion of the Investigator until it has returned', 'to the normal range or stabilized, and/or a diagnosis is made to adequately explain the', 'abnormality. Additional safety laboratories and assessments as indicated by the clinical situation', 'may be requested. Clinical laboratory assessments are listed in Table 5 and will be assessed as', 'specified in the Schedule of Assessments (Table 1).', 'While local laboratory results may be used for urgent clinical and dosing decisions, on the day of', 'the clinic visit assessments, all laboratory assessments specified in Table 5 which are performed', 'at the clinic should also be sent in parallel to the central laboratory. In the case of discrepant', 'local and central laboratory results on samples drawn on the same day, central laboratory results', 'will be relied upon for clinical and dosing decisions.', 'Clinical laboratory assessments may be collected at the clinical site or at home by a trained', 'healthcare professional. It is preferred that clinical laboratory assessments be drawn via', 'peripheral draw (ie, fresh stick), however in cases where peripheral access is not possible', 'existing indwelling venous access may be utilized.', 'Please see Section 6.2.3.1 for the LFT monitoring and dosing plan.', 'Property of the Sanofi Group - strictly confidential', '57']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'Table 5:', 'Clinical Laboratory Assessments', 'Hematology', 'Hematocrit', 'Neutrophils, absolute and %', 'Hemoglobin', 'Lymphocytes, absolute and %', 'RBC count', 'Monocytes, absolute and %', 'WBC count', 'Eosinophils, absolute and %', 'Mean corpuscular volume', 'Basophils, absolute and %', 'Mean corpuscular hemoglobin', 'Platelet count', 'CD4 in HIV-positive patients', 'Mean corpuscular hemoglobin concentration', '(at Screening only)', 'Serum Chemistry', 'Sodium', 'Potassium', 'BUN', 'Phosphate', 'Creatinine and eGFR (using the MDRD formula)', 'Albumin', 'Glucose', 'Calcium', 'Chloride', 'Carbon dioxide', 'Liver Function Tests (LFTs)', 'AST', 'ALP', 'ALT', 'Bilirubin (total and direct)', 'GGT', 'Coagulation', 'Prothrombin time', 'Activated partial thromboplastin time', 'INR', 'Fibrinogen', 'D-dimer', 'Prothrombin fragment 1, 2', 'Factor Activity', 'FVIII activity for patients with hemophilia A', 'FIX activity for patients with hemophilia B', 'Urinalysis', 'Visual inspection for appearance and color', 'Bilirubin', 'pH (dipstick)', 'Nitrite', 'Specific gravity', 'RBCs', 'Ketones', 'Urobilinogen', 'Glucose', 'Leukocytes', 'Protein', 'Microscopy (if clinically indicated)', 'Property of the Sanofi Group - strictly confidential', '58']\n\n###\n\n", "completion": "END"}